Monte Rosa Therapeutics (GLUE) Preferred Stock Liabilities (2020)

Monte Rosa Therapeutics (GLUE) recorded quarterly Preferred Stock Liabilities of $67.8 million in Q4 2020.

Monte Rosa Therapeutics (GLUE) Preferred Stock Liabilities (2020) Analysis & Trends

Monte Rosa Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $67.8 million for Q4 2020.

In Q4 2020, Preferred Stock Liabilities changed N/A year-over-year to $67.8 million; the TTM figure through Dec 2020 stood at $67.8 million (changed N/A YoY), while the FY2020 annual figure was $67.8 million, changed N/A from the prior year.
Preferred Stock Liabilities was $67.8 million for Q4 2020 at Monte Rosa Therapeutics.
In the past five years, Preferred Stock Liabilities ranged from a high of $67.8 million in Q4 2020 to a low of $67.8 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Monte Rosa Therapeutics	1.83 Bn	1.15 Bn	-	-

Download Data

Date	Value
Dec 31, 2020	67.76 Mn